(CercleFinance.com) – The company dedicated to women’s health Mithra fell by almost 30% this Tuesday on Euronext Brussels after announcing that it had less than a month of financial visibility.
The company’s current cash position, which amounts to 6.5 million euros, should cover its current cash requirements until the beginning of March, according to a press release published this morning.
Mithra says it has started discussions with its creditors in order to extend its financial room for maneuver, some of them having already indicated to it that they were ready to enter into dialogue.
In recent months, the group has studied various strategic options with a view, in particular, to selling certain assets and raising additional equity capital.
The company explains that it is still looking to sell or license various assets and is evaluating the best strategic alternatives for two of its secondary activities: Novalon, its complex therapeutics business, as well as its CDMO (pharmaceutical outsourcing) businesses. peak.
Its management further plans to enter into licensing and supply agreement(s) for Donesta (menopause) for the United States in 2024, which is expected to generate upfront payments, supply revenues and royalties.
Mithra plans to present its results for the full year 2023 on March 8.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
